Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segment Glomerulosclerosis: A Two Part Prospective Study of H.P. Acthar (PODOCYTE)
Sponsor: |
Mallinckrodt |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ6352 |
U.S. Govt. ID: |
NCT02633046 |
Contact: |
Wooin Ahn, MD: 212-305-0320 / wa2197@cumc.columbia.edu |
Focal Segmental Glomerulosclerosis (FSGS) is a disease in which your kidneys allow an excess amount of protein in your urine. Too much protein in the urine (also called proteinuria) is a medical condition called nephrotic syndrome. The purpose of this clinical trial is to evaluate the safety and effectiveness of the study drug, Acthar, in adult patients with FSGS who have failed prior treatments.
This study is closed
Investigator
Wooin Ahn, MD
Are you at least 18 years of age? |
Yes |
No |
Have you been diagnosed with Focal Segmental Glomerulosclerosis (FSGS)? |
Yes |
No |